S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
NASDAQ:SAVA

Cassava Sciences (SAVA) Stock Price, News & Analysis

$20.42
+0.71 (+3.60%)
(As of 03/27/2024 ET)
Today's Range
$19.62
$20.48
50-Day Range
$18.44
$26.39
52-Week Range
$12.32
$32.10
Volume
376,429 shs
Average Volume
735,343 shs
Market Capitalization
$882.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$124.00

Cassava Sciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
507.2% Upside
$124.00 Price Target
Short Interest
Bearish
30.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
0.25mentions of Cassava Sciences in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.01) to $1.67 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.44 out of 5 stars

Medical Sector

272nd out of 939 stocks

Pharmaceutical Preparations Industry

123rd out of 431 stocks

SAVA stock logo

About Cassava Sciences Stock (NASDAQ:SAVA)

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

SAVA Stock Price History

SAVA Stock News Headlines

Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Cassava Sciences (NASDAQ:SAVA) Trading Down 5.1%
SAVA Apr 2024 23.500 call
SAVA Jun 2025 30.000 call
SAVA Jun 2025 10.000 put
SAVA Apr 2024 20.500 put
SAVA Mar 2024 19.500 put
SAVA Mar 2024 11.000 put
SAVA Mar 2024 17.500 call
SAVA Jan 2025 2.500 call
See More Headlines
Receive SAVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SAVA
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$124.00
High Stock Price Target
$124.00
Low Stock Price Target
$124.00
Potential Upside/Downside
+507.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-97,220,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.26 per share

Miscellaneous

Free Float
38,859,000
Market Cap
$882.55 million
Optionable
Optionable
Beta
-0.42
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Remi Barbier (Age 64)
    Founder, Chairman, President & CEO
    Comp: $1.11M
  • Mr. Eric J. Schoen (Age 56)
    Chief Financial Officer
    Comp: $426.61k
  • Mr. R. Christopher Cook (Age 59)
    Senior VP, Company Secretary & General Counsel
    Comp: $457.64k
  • Dr. James W. Kupiec M.D. (Age 70)
    Chief Medical Officer
    Comp: $400k
  • Dr. George Thornton Ph.D.
    Senior Vice President of Technology
  • Mr. Michael Zamloot
    Senior Vice President of Technical Operations
  • Dr. Michael Marsman Pharm.D.
    Senior Vice President of Regulatory Affairs
  • Dr. Lindsay H. Burns Ph.D.
    Senior Vice President of Neuroscience

SAVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Cassava Sciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SAVA shares.
View SAVA analyst ratings
or view top-rated stocks.

What is Cassava Sciences' stock price target for 2024?

1 Wall Street research analysts have issued twelve-month target prices for Cassava Sciences' shares. Their SAVA share price targets range from $124.00 to $124.00. On average, they anticipate the company's stock price to reach $124.00 in the next year. This suggests a possible upside of 507.2% from the stock's current price.
View analysts price targets for SAVA
or view top-rated stocks among Wall Street analysts.

How have SAVA shares performed in 2024?

Cassava Sciences' stock was trading at $22.51 on January 1st, 2024. Since then, SAVA stock has decreased by 9.3% and is now trading at $20.42.
View the best growth stocks for 2024 here
.

When is Cassava Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our SAVA earnings forecast
.

How were Cassava Sciences' earnings last quarter?

Cassava Sciences, Inc. (NASDAQ:SAVA) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.10.

What ETFs hold Cassava Sciences' stock?
When did Cassava Sciences' stock split?

Shares of Cassava Sciences split on the morning of Thursday, December 21st 2023. The 14-10 split was announced on Thursday, December 21st 2023. The newly issued shares were issued to shareholders after the closing bell on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split.

What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA).

Who are Cassava Sciences' major shareholders?

Cassava Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.51%), Vanguard Group Inc. (5.38%), Gallacher Capital Management LLC (1.38%), Northern Trust Corp (0.92%), Charles Schwab Investment Management Inc. (0.73%) and Nuveen Asset Management LLC (0.66%). Insiders that own company stock include Eric Schoen, James William Kupiec, Richard Barry and Sanford Robertson.
View institutional ownership trends
.

How do I buy shares of Cassava Sciences?

Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SAVA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners